Drug Approval | February 24, 2026
Ultragenyx bags FDA priority review for groundbreaking GSDIa gene therapy
If approved, DTX401 would be the first treatment to address the disease at its root cause
If approved, DTX401 would be the first treatment to address the disease at its root cause
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Subscribe To Our Newsletter & Stay Updated
